Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 198 participants.

Also called NCT03476616

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 198 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03476616
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Greece (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03476616. Randomized; no masking; primary purpose treatment. Start 2018-09-01 (actual); primary completion 2025-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients
Acronym
HEBRO
Condition
Hypertension
Condition
Obesity
Intervention (Drug)
Eplerenone (-based therapy) arm
Intervention (Drug)
Valsartan (-based therapy) arm
Lead sponsor
Hippocration General Hospital (class: other)

Record details

Record id
cardio:ct-nct03476616
Content hash
8913e3386451c6c8313dafdbfe6a4773a3032751dc574122df5b6aba1e89bb08